Corrigendum

Abstract

In the Results section, page 7, the text is corrected from “Concomitant use of DOACs and antiplatelet agents was associated with a decreased risk of major bleeding among male patients (weighted HR, 0.54; 95% CI, 0.30–0.96; I2, 0.00) but not among female patients (weighted HR, 1.05; 95% CI, 0.62–1.77; I2, 0.00). [...]while there was no association between concomitant use of DOACs and antiplatelet agents and the risk of all-cause mortality among male patients (weighted HR, 0.95; 95% CI, 0.56–1.60; I2, 0.00), there was a nonsignificant trend toward an increased risk among female patients (weighted HR, 1.64; 95% CI, 0.98–2.72; I2, 0.00). Importantly, the programming error did not affect any of the results of the primary analyses. [...]the main conclusions of the study remain unchanged. The corrected Tables are given below. 1-3 TABLE 2 Baseline characteristics of patients with VTE initiating concomitant use of oral anticoagulants and antiplatelet agents before and after propensity score weighting (InGef database) Characteristic a Before weighting After weighting DOACs + APs (n = 1234) VKAs + APs (n = 493) SMD DOACs + APs (n = 1235) VKAs + APs (n = 489) SMD Age, in years (mean, SD) 74.8 11.8 72.7 11.1 0.181 74.2 11.6 74.0 11.5 0.016 Female sex 549 44.5 201 40.8 0.075 535 43.3 209 42.6 0.014 Comorbidities Obesity <5 – 0 0.0 NA – – – – NA Varicose veins/PTS 36 2.9 12 2.4 0.029 35 2.9 15 3.1 −0.016 Arterial hypertension 1,140 92.4 449 91.1 0.048 1,135 91.9 448 91.6 0.011 Congestive heart failure 479 38.8 189 38.3 0.010 477 38.6 182 37.3 0.028 Myocardial infarction 174 14.1 63 12.8 0.038 170 13.8 65 13.3 0.013 Stroke 293 23.7 91 18.5 0.127 275 22.3 112 22.8 −0.013 Diabetes mellitus 513 41.6 210 42.6 −0.021 519 42.1 210 43.0 −0.018 Chronic kidney disease 320 25.9 179 36.3 −0.230 357 28.9 141 28.9 0.000 Moderate to severe liver disease 11 0.9 5 1.0 NA – – – – NA Inflammatory bowel disease 20 1.6 16 3.3 −0.114 26 2.1 10 2.1 0.002 Cancer 298 24.2 109 22.1 0.048 291 23.6 113 23.1 0.011 Bleeding 234 19.0 91 18.5 0.013 233 18.9 90 18.4 0.012 Fracture 81 6.6 18 3.7 0.126 71 5.7 27 5.4 0.013 Major surgery 472 38.3 209 42.4 −0.085 486 39.4 189 38.6 0.017 Comedications APs, duration in days (mean, SD) 195.8 125.7 179.6 127.0 0.128 190.6 126.3 188.6 126.5 0.015 Oral contraceptives 9 0.7 6 1.2 NA – – – – NA Hormone replacement therapy 0 0.0 0 0.0 NA – – – – NA Tamoxifen 7 0.6 7 1.4 NA – – – – NA Systemic corticosteroids 248 20.1 96 19.5 0.016 244 19.8 95 19.4 0.010 SSRIs 133 10.8 45 9.1 0.054 127 10.3 49 10.1 0.007 Proton pump inhibitors 756 61.3 277 56.2 0.104 739 59.8 293 59.9 −0.002 NSAIDs 470 38.1 191 38.7 −0.013 474 38.4 193 39.5 −0.021 Proxies of overall health Number of hospitalizations 0 417.00 33.79 158.00 32.05 0.037 411.31 33.32 164.10 33.53 −0.005 1 356.00 28.85 146.00 29.61 −0.017 359.76 29.14 142.18 29.05 0.002 2 195.00 15.80 96.00 19.47 −0.098 208.73 16.91 82.40 16.84 0.002 >2 266.00 21.56 93.00 18.86 0.066 254.71 20.63 100.69 20.58 0.001 Number of non-antithrombotic drugs 0–10 561.00 45.46 235.00 47.67 −0.044 568.90 46.08 225.64 46.11 −0.001 11–15 386.00 31.28 129.00 26.17 0.112 366.87 29.72 142.12 29.04 0.015 ≥16 287.00 23.26 129.00 26.17 −0.068 298.73 24.20 121.60 24.85 −0.015 Note: S Suppressed due to small numbers (<5) as per confidentiality agreement with the data custodians contributing data to the InGef database.